BR112013031572A2 - produto de combinação farmacêutica, e, inalador de pó seco. - Google Patents

produto de combinação farmacêutica, e, inalador de pó seco.

Info

Publication number
BR112013031572A2
BR112013031572A2 BR112013031572A BR112013031572A BR112013031572A2 BR 112013031572 A2 BR112013031572 A2 BR 112013031572A2 BR 112013031572 A BR112013031572 A BR 112013031572A BR 112013031572 A BR112013031572 A BR 112013031572A BR 112013031572 A2 BR112013031572 A2 BR 112013031572A2
Authority
BR
Brazil
Prior art keywords
dry powder
powder inhaler
pharmaceutical combination
combination product
pharmaceutical
Prior art date
Application number
BR112013031572A
Other languages
English (en)
Inventor
Crater Glenn
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BR112013031572A2 publication Critical patent/BR112013031572A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
BR112013031572A 2011-06-08 2012-06-01 produto de combinação farmacêutica, e, inalador de pó seco. BR112013031572A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161494600P 2011-06-08 2011-06-08
PCT/EP2012/060444 WO2012168161A1 (en) 2011-06-08 2012-06-01 Combination comprising umeclidinium and a corticosteroid

Publications (1)

Publication Number Publication Date
BR112013031572A2 true BR112013031572A2 (pt) 2017-03-21

Family

ID=46201674

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013031572A BR112013031572A2 (pt) 2011-06-08 2012-06-01 produto de combinação farmacêutica, e, inalador de pó seco.

Country Status (19)

Country Link
US (1) US20140113888A1 (pt)
EP (1) EP2717868A1 (pt)
JP (1) JP2014516062A (pt)
KR (1) KR20140041699A (pt)
CN (1) CN103582477A (pt)
AU (1) AU2012266541A1 (pt)
BR (1) BR112013031572A2 (pt)
CA (1) CA2838030A1 (pt)
CL (1) CL2013003497A1 (pt)
CO (1) CO6821951A2 (pt)
CR (1) CR20130643A (pt)
DO (1) DOP2013000290A (pt)
EA (1) EA201391618A1 (pt)
IL (1) IL229633A0 (pt)
MA (1) MA35406B1 (pt)
MX (1) MX2013014399A (pt)
PE (1) PE20141048A1 (pt)
SG (1) SG195262A1 (pt)
WO (1) WO2012168161A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2800194B1 (en) 2011-12-28 2017-06-28 Asahi Kasei Kabushiki Kaisha Redox flow secondary battery and electrolyte membrane for redox flow secondary battery
JP6267685B2 (ja) 2012-04-13 2018-01-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 集合粒子
GB201222679D0 (en) * 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
ES2959699T3 (es) 2014-05-28 2024-02-27 Glaxosmithkline Ip Dev Ltd Furoato de fluticasona en el tratamiento de la EPOC
EP3157567A1 (en) 2014-06-18 2017-04-26 Cipla Limited Pharmaceutical composition comprising a beta-2-agonist and anticholinergic agent
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技(上海)有限公司 奎宁环衍生物及其制备方法和用途
TR201712424A2 (tr) * 2017-08-21 2019-03-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
WO2021236570A1 (en) * 2020-05-18 2021-11-25 Anovent Pharmaceutical (U.S.), Llc Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
WO1994021229A1 (en) 1993-03-17 1994-09-29 Minnesota Mining And Manufacturing Company Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
CO5310534A1 (es) 2000-08-05 2003-08-29 Glaxo Group Ltd Nuevos derivados de androstano anti-inflamatorios
UA77656C2 (en) * 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
SE527191C2 (sv) * 2003-06-19 2006-01-17 Microdrug Ag Inhalatoranordning samt kombinerade doser av tiotropium och fluticason
UY28871A1 (es) 2004-04-27 2005-11-30 Glaxo Group Ltd Antagonistas del receptor de acetilcolina muscarinico
PE20060826A1 (es) * 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
JP2010539182A (ja) * 2007-09-12 2010-12-16 グラクソ グループ リミテッド 治療剤の新規組み合わせ
ES2739352T3 (es) * 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
MX2013014399A (es) 2014-03-21
CL2013003497A1 (es) 2014-07-04
AU2012266541A1 (en) 2014-01-09
CN103582477A (zh) 2014-02-12
DOP2013000290A (es) 2014-03-16
IL229633A0 (en) 2014-01-30
EA201391618A1 (ru) 2014-05-30
CA2838030A1 (en) 2012-12-13
US20140113888A1 (en) 2014-04-24
KR20140041699A (ko) 2014-04-04
MA35406B1 (fr) 2014-09-01
JP2014516062A (ja) 2014-07-07
PE20141048A1 (es) 2014-09-08
SG195262A1 (en) 2013-12-30
EP2717868A1 (en) 2014-04-16
CR20130643A (es) 2014-02-04
CO6821951A2 (es) 2013-12-31
NZ618166A (en) 2016-01-29
WO2012168161A1 (en) 2012-12-13

Similar Documents

Publication Publication Date Title
BR112013031572A2 (pt) produto de combinação farmacêutica, e, inalador de pó seco.
BR112015000529A2 (pt) métodos e sistemas de entrega de fármaco de pó seco
BR112015004233A2 (pt) inalador.
BR112015002738A2 (pt) composto , e , composição farmacêutica
IL233154A (en) Compounds, pharmaceuticals containing them and their uses
FR2968566B1 (fr) Inhalateur de poudre seche.
FR2962343B1 (fr) Inhalateur de poudre seche.
EP2746283A4 (en) PYRIMIDOPYRIMIDONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES
BR112014004921A2 (pt) dispositivo inalador de pó seco
BR112014029403A2 (pt) conjugados, anticorpo e formulação farmacêutica
BR112014027730A2 (pt) material, e material não tecido
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
IL236057B (en) History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them
BR112013032688A2 (pt) artigo, e, cigarro
BR112015002824A2 (pt) composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação.
IL243734A0 (en) History of oxoquinazolinyl-butanamide, their preparation containing them
FR2962338B1 (fr) Inhalateur de poudre seche.
BR112015001597A2 (pt) contêiner dobrável,e, dispensador
FR2962342B1 (fr) Inhalateur de poudre seche.
IL243733A0 (en) Cyclopentane history, their preparation and medicines containing them
HK1202296A1 (en) Anti-adamts-5 antibody, derivatives and uses thereof adamts-5
BR112014000166A2 (pt) sistema de acondicionamento e de aplicação de produto, notadamente de produto cosmético
CL2014003283A1 (es) Formulación farmacéutica.
BR112015001787A2 (pt) rolamento de triturador giratório.
FR2962337B1 (fr) Inhalateur de poudre seche.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]